Literature DB >> 21557933

Mechanisms of transthyretin cardiomyocyte toxicity inhibition by resveratrol analogs.

Steve Bourgault1, Sungwook Choi, Joel N Buxbaum, Jeffery W Kelly, Joshua L Price, Natàlia Reixach.   

Abstract

The transthyretin amyloidoses are a subset of protein misfolding diseases characterized by the extracellular deposition of aggregates derived from the plasma homotetrameric protein transthyretin (TTR) in peripheral nerves and the heart. We have established a robust disease-relevant human cardiac tissue culture system to explore the cytotoxic effects of amyloidogenic TTR variants. We have employed this cardiac amyloidosis tissue culture model to screen 23 resveratrol analogs as inhibitors of amyloidogenic TTR-induced cytotoxicity and to investigate their mechanisms of protection. Resveratrol and its analogs kinetically stabilize the native tetramer preventing the formation of cytotoxic species. In addition, we demonstrate that resveratrol can accelerate the formation of soluble non-toxic aggregates and that the resveratrol analogs tested can bring together monomeric TTR subunits to form non-toxic native tetrameric TTR.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21557933      PMCID: PMC3145458          DOI: 10.1016/j.bbrc.2011.04.133

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  34 in total

1.  Sulfated glycosaminoglycans accelerate transthyretin amyloidogenesis by quaternary structural conversion.

Authors:  Steve Bourgault; James P Solomon; Natàlia Reixach; Jeffery W Kelly
Journal:  Biochemistry       Date:  2011-01-24       Impact factor: 3.162

2.  Heparan sulfate/heparin promotes transthyretin fibrillization through selective binding to a basic motif in the protein.

Authors:  Fredrik Noborn; Paul O'Callaghan; Erik Hermansson; Xiao Zhang; John B Ancsin; Ana M Damas; Ingrid Dacklin; Jenny Presto; Jan Johansson; Maria J Saraiva; Erik Lundgren; Robert Kisilevsky; Per Westermark; Jin-Ping Li
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-21       Impact factor: 11.205

3.  Prefibrillar transthyretin oligomers and cold stored native tetrameric transthyretin are cytotoxic in cell culture.

Authors:  Karin Sörgjerd; Therése Klingstedt; Mikael Lindgren; Katarina Kågedal; Per Hammarström
Journal:  Biochem Biophys Res Commun       Date:  2008-11-05       Impact factor: 3.575

4.  A substructure combination strategy to create potent and selective transthyretin kinetic stabilizers that prevent amyloidogenesis and cytotoxicity.

Authors:  Sungwook Choi; Natàlia Reixach; Stephen Connelly; Steven M Johnson; Ian A Wilson; Jeffery W Kelly
Journal:  J Am Chem Soc       Date:  2010-02-03       Impact factor: 15.419

5.  Toward optimization of the linker substructure common to transthyretin amyloidogenesis inhibitors using biochemical and structural studies.

Authors:  Steven M Johnson; Stephen Connelly; Ian A Wilson; Jeffery W Kelly
Journal:  J Med Chem       Date:  2008-09-24       Impact factor: 7.446

6.  Chemoselective small molecules that covalently modify one lysine in a non-enzyme protein in plasma.

Authors:  Sungwook Choi; Stephen Connelly; Natàlia Reixach; Ian A Wilson; Jeffery W Kelly
Journal:  Nat Chem Biol       Date:  2010-02       Impact factor: 15.040

7.  Transthyretin protects Alzheimer's mice from the behavioral and biochemical effects of Abeta toxicity.

Authors:  Joel N Buxbaum; Zhengyi Ye; Natàlia Reixach; Linsey Friske; Coree Levy; Pritam Das; Todd Golde; Eliezer Masliah; Amanda R Roberts; Tamas Bartfai
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-12       Impact factor: 11.205

Review 8.  Transthyretin: the servant of many masters.

Authors:  Joel N Buxbaum; Natàlia Reixach
Journal:  Cell Mol Life Sci       Date:  2009-07-31       Impact factor: 9.261

9.  A primer of amyloid nomenclature.

Authors:  Per Westermark; Merrill D Benson; Joel N Buxbaum; Alan S Cohen; Blas Frangione; Shu-Ichi Ikeda; Colin L Masters; Giampaolo Merlini; Maria J Saraiva; Jean D Sipe
Journal:  Amyloid       Date:  2007-09       Impact factor: 7.141

10.  Formation of cytotoxic transthyretin is not dependent on inter-molecular disulphide bridges commonly found within the amyloid form.

Authors:  M Lindhagen-Persson; M Vestling; N Reixach; A Olofsson
Journal:  Amyloid       Date:  2008-12       Impact factor: 7.141

View more
  28 in total

1.  Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade.

Authors:  Christine E Bulawa; Stephen Connelly; Michael Devit; Lan Wang; Charlotte Weigel; James A Fleming; Jeff Packman; Evan T Powers; R Luke Wiseman; Theodore R Foss; Ian A Wilson; Jeffery W Kelly; Richard Labaudinière
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-29       Impact factor: 11.205

2.  Mechanistic basis for the recognition of a misfolded protein by the molecular chaperone Hsp90.

Authors:  Javier Oroz; Jin Hae Kim; Bliss J Chang; Markus Zweckstetter
Journal:  Nat Struct Mol Biol       Date:  2017-02-20       Impact factor: 15.369

3.  Age-related oxidative modifications of transthyretin modulate its amyloidogenicity.

Authors:  Lei Zhao; Joel N Buxbaum; Natàlia Reixach
Journal:  Biochemistry       Date:  2013-03-04       Impact factor: 3.162

Review 4.  The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug.

Authors:  Steven M Johnson; Stephen Connelly; Colleen Fearns; Evan T Powers; Jeffery W Kelly
Journal:  J Mol Biol       Date:  2012-01-05       Impact factor: 5.469

5.  Stilbene Boronic Acids Form a Covalent Bond with Human Transthyretin and Inhibit Its Aggregation.

Authors:  Thomas P Smith; Ian W Windsor; Katrina T Forest; Ronald T Raines
Journal:  J Med Chem       Date:  2017-09-18       Impact factor: 7.446

6.  Mutasynthesis of a potent anticancer sibiromycin analogue.

Authors:  Isaac T Yonemoto; Wei Li; Ankush Khullar; Natàlia Reixach; Barbara Gerratana
Journal:  ACS Chem Biol       Date:  2012-03-23       Impact factor: 5.100

7.  Potent kinetic stabilizers that prevent transthyretin-mediated cardiomyocyte proteotoxicity.

Authors:  Mamoun M Alhamadsheh; Stephen Connelly; Ahryon Cho; Natàlia Reixach; Evan T Powers; Dorothy W Pan; Ian A Wilson; Jeffery W Kelly; Isabella A Graef
Journal:  Sci Transl Med       Date:  2011-08-24       Impact factor: 17.956

8.  Transthyretin deposition in articular cartilage: a novel mechanism in the pathogenesis of osteoarthritis.

Authors:  Yukio Akasaki; Natàlia Reixach; Tokio Matsuzaki; Oscar Alvarez-Garcia; Merissa Olmer; Yukihide Iwamoto; Joel N Buxbaum; Martin K Lotz
Journal:  Arthritis Rheumatol       Date:  2015-05       Impact factor: 10.995

9.  AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin.

Authors:  Sravan C Penchala; Stephen Connelly; Yu Wang; Miki S Park; Lei Zhao; Aleksandra Baranczak; Irit Rappley; Hannes Vogel; Michaela Liedtke; Ronald M Witteles; Evan T Powers; Natàlia Reixach; William K Chan; Ian A Wilson; Jeffery W Kelly; Isabella A Graef; Mamoun M Alhamadsheh
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-28       Impact factor: 11.205

10.  Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction.

Authors:  Selma F Mohammed; Sultan A Mirzoyev; William D Edwards; Ahmet Dogan; Donna R Grogan; Shannon M Dunlay; Veronique L Roger; Morie A Gertz; Angela Dispenzieri; Steven R Zeldenrust; Margaret M Redfield
Journal:  JACC Heart Fail       Date:  2014-04       Impact factor: 12.035

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.